← Back to all trials
Recruiting
NCT07112378
A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis
Conditions: Eosinophilic Esophagitis (EoE)
Sex: All
Ages: 6 Months – 6 Years
Healthy volunteers: No
Phase: PHASE3
Enrollment: 20
Sponsor: Regeneron Pharmaceuticals
Location: Phoenix Childrens Hospital Phoenix Arizona
Summary
This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment.
The aim of the study is to see how safe, tolerable, and effective the study drug is when given for 24 weeks to children with active EoE.
The study is looking at several other research questions, including:
* What side effects may happen from taking the study drug
* How much study drug is in the blood at different times
* Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)
Eligibility Criteria
Key Inclusion Criteria:
1. Pediatric patients aged ≥6 months and weighing ≥5 kg and \
Source: ClinicalTrials.gov (NCT07112378). StuddyBuddy aggregates publicly available trial information.